Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
News|Articles|February 21, 2025
AJMC® in the Press, February 21, 2025
Author(s)Julia Bonavitacola
Listen
0:00 / 0:00
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An article from
Advertisement
Related to this article
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
4
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
5